Clinical Outcomes of Estrogen Negative- Progesterone Positive Invasive Breast Cancer, Retrospective Study

Background Breast cancer is comprised of a heterogeneous subtypes. The decisions of treatment depend on the tumor expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER 2). These biomarkers have prognostic and predictive significances. Material and methods 100 patients from 2008 to 2012 were identified and analyzed. Patients were classified into three hormonal receptors subtypes ER-/PR+, ER+/PR, and ER-/PR-. Analysis of the clinicopathological features, treatment, recurrence, survival rate and prognostic factor were compared. Results The subtype ER-/PR+ was seen frequently in young age with large size tumor and lymph node metastasis, higher stage and histologic grade when compared with the other two subtypes. Analysis of the frequency of recurrence revealed that local recurrence, distant metastasis and number of deaths did not differ statistically and hence no difference in disease free survival (DFS) and overall survival (OS). The 5 years DFS was 37.5 %, 20.3 % and 21.7 % in ER-/PR+, ER+/PR and ER-/PR- groups respectively. Conclusion& Recommendation The breast cancer subtypes according to the ER and PR are biologically and clinically different groups. Assessment of PR is recommended as it can provide important prognostic information and prediction of response to adjuvant HT in ER- tumors.